ZA200809192B - Use of strobilurins for treating malfunctions of the iron metabolism - Google Patents

Use of strobilurins for treating malfunctions of the iron metabolism

Info

Publication number
ZA200809192B
ZA200809192B ZA200809192A ZA200809192A ZA200809192B ZA 200809192 B ZA200809192 B ZA 200809192B ZA 200809192 A ZA200809192 A ZA 200809192A ZA 200809192 A ZA200809192 A ZA 200809192A ZA 200809192 B ZA200809192 B ZA 200809192B
Authority
ZA
South Africa
Prior art keywords
strobilurins
iron metabolism
malfunctions
treating
treating malfunctions
Prior art date
Application number
ZA200809192A
Other languages
English (en)
Inventor
Heinz Kieczka
Ravenzwaay Bennard Van
Werner Mellert
Palermo Cunha Georgia Coelho
Klaus Deckardt
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200809192(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basf Se filed Critical Basf Se
Publication of ZA200809192B publication Critical patent/ZA200809192B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200809192A 2006-03-29 2008-10-27 Use of strobilurins for treating malfunctions of the iron metabolism ZA200809192B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111933 2006-03-29

Publications (1)

Publication Number Publication Date
ZA200809192B true ZA200809192B (en) 2010-01-27

Family

ID=38284013

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200809192A ZA200809192B (en) 2006-03-29 2008-10-27 Use of strobilurins for treating malfunctions of the iron metabolism

Country Status (16)

Country Link
US (1) US20100234366A1 (ko)
EP (1) EP2001555A1 (ko)
JP (1) JP2009531379A (ko)
KR (1) KR20080111021A (ko)
CN (1) CN101448550A (ko)
AR (1) AR060178A1 (ko)
AU (1) AU2007233829A1 (ko)
BR (1) BRPI0710209A2 (ko)
CA (1) CA2646209C (ko)
CL (1) CL2007000836A1 (ko)
EA (1) EA200801940A1 (ko)
IL (1) IL194159A0 (ko)
MX (1) MX2008012317A (ko)
TW (1) TW200812592A (ko)
WO (1) WO2007113170A1 (ko)
ZA (1) ZA200809192B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101290745B1 (ko) 2010-06-03 2013-07-29 한국해양과학기술원 라말린을 함유하는 염증질환 또는 면역질환의 예방 또는 치료용 약학 조성물
JP7288092B2 (ja) 2019-06-28 2023-06-06 ザ プロクター アンド ギャンブル カンパニー 相乗的抗炎症性組成物
US11980612B2 (en) 2020-06-26 2024-05-14 The Procter & Gamble Company Synergistic anti-inflammatory compositions
US11701316B2 (en) 2020-12-18 2023-07-18 The Procter & Gamble Company Synergistic anti-inflammatory compositions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37873A (en) * 1863-03-10 Improvement in hay-presses
US33989A (en) * 1861-12-24 Improvement it machines for punching boiler-plates
US37839A (en) * 1863-03-03 Improved spoke-machine
DE3623921A1 (de) * 1986-07-16 1988-01-21 Basf Ag Oximether und diese enthaltende fungizide
DE3705389A1 (de) * 1987-02-20 1988-09-01 Basf Ag Substituierte crotonsaeureester und diese enthaltende fungizide
DE3823991A1 (de) * 1988-07-15 1990-02-15 Basf Ag Heterocyclisch substituierte (alpha)-aryl-acrylsaeureester und fungizide, die diese verbindungen enthalten
US5194438A (en) * 1988-07-15 1993-03-16 Basf Aktiengesellschaft α-arylacrylates substituted by a trifluoromethylpyrimidinyloxy radical, fungicidal compositions and methods
DE3905911A1 (de) * 1989-02-25 1990-08-30 Basf Ag Neue ss-methoxyacrylate, ihre herstellung und verwendung
PH11991042549B1 (ko) * 1990-06-05 2000-12-04
ES2120100T3 (es) * 1990-06-27 1998-10-16 Basf Ag O-bencil-oximeteres y agentes protectores de las plantas que contienen estos compuestos.
DE4030038A1 (de) * 1990-09-22 1992-03-26 Basf Ag Ortho-substituierte phenylessigsaeureamide
DE4117371A1 (de) * 1991-05-28 1992-12-03 Basf Ag Antimykotische mittel, die phenylessigsaeurederivate enthalten
SK283351B6 (sk) * 1992-01-29 2003-06-03 Basf Aktiengesellschaft Karbamáty a fungicídne prostriedky s ich obsahom
DE4318917A1 (de) * 1993-06-07 1994-12-08 Bayer Ag 2-Oximino-2-phenyl-acetamide
JP3307396B2 (ja) * 1994-02-04 2002-07-24 ビーエーエスエフ アクチェンゲゼルシャフト フェニル酢酸誘導体、これを製造するための方法および中間生成物、並びにこれを含有する薬剤
ATE236119T1 (de) * 1994-02-04 2003-04-15 Basf Ag Phenylessigsäurederivate, verfahren und zwischenprodukte zu ihrer herstellung und sie enthaltende mittel
DE4423612A1 (de) * 1994-07-06 1996-01-11 Basf Ag 2-[(Dihydro)pyrazolyl-3'-oxymethylen]-anilide, Verfahren zu ihrer Herstelung und ihre Verwendung
DE19539324A1 (de) * 1995-10-23 1997-04-24 Basf Ag Phenylessigsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und sie enthaltende Mittel
US6084120A (en) * 1997-07-09 2000-07-04 Hoffmann-La Roche Inc. β-Alkoxyacrylates against malaria
IT1303688B1 (it) * 1998-11-02 2001-02-23 Medidom Lab Derivati aromatici e relativi complessi di fe(iii) atti all'usocome agenti normalizzanti del livello di ferro nell'organismo.
AU2293101A (en) * 1999-12-21 2001-07-03 Geltex Pharmaceuticals, Inc. Method for making hbed
BR0308325A8 (pt) * 2002-03-11 2018-03-20 Basf Se método para imunizar plantas contra bacterioses, e, uso de um composto
DE10211428A1 (de) * 2002-03-15 2003-10-23 Bayer Ag Bekämpfung von Parasiten an Tieren durch Halogenpyrimidine
EP2011489A3 (en) * 2002-07-09 2009-04-22 Roberta Gottlieb Method to inhibit ischemia and reperfusion injury
US20050032903A1 (en) * 2003-08-08 2005-02-10 Suarez-Cervieri Miguel Octavio Method for controlling fungal sieases in legumes
KR100624238B1 (ko) * 2004-06-22 2006-09-19 한국화학연구원 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물

Also Published As

Publication number Publication date
US20100234366A1 (en) 2010-09-16
AU2007233829A1 (en) 2007-10-11
EA200801940A1 (ru) 2009-04-28
AR060178A1 (es) 2008-05-28
CL2007000836A1 (es) 2008-05-23
IL194159A0 (en) 2011-08-01
WO2007113170A1 (de) 2007-10-11
JP2009531379A (ja) 2009-09-03
CA2646209A1 (en) 2007-10-11
EP2001555A1 (de) 2008-12-17
CA2646209C (en) 2011-08-16
BRPI0710209A2 (pt) 2011-05-24
TW200812592A (en) 2008-03-16
CN101448550A (zh) 2009-06-03
MX2008012317A (es) 2008-10-10
KR20080111021A (ko) 2008-12-22

Similar Documents

Publication Publication Date Title
IL197001A0 (en) Combination treatment for metabolic disorders
EP1976377A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP2019675A4 (en) METHODS FOR TREATING OR PREVENTING NEOPLASIA
GB2456853B (en) Metal treatment
EP1983972A4 (en) COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
ZA200808963B (en) Compounds for the treatment of metabolic disorders
EP1983097A4 (en) Iron and Iron with it
IL196559A0 (en) Combination therapy
EP2214518A4 (en) METABOLIC IMPROVEMENT TREATMENT
IL196556A0 (en) Combination therapy
EP2123270A4 (en) MEANS TO IMPROVE THE IRON FLUID CHANGE
ZA200805645B (en) Compounds for the treatment of metabolic disorders
EP2054061A4 (en) COMBINATION THERAPY
GB0608042D0 (en) Steam iron
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
PL2122041T3 (pl) Żelazko do prasowania
ZA200809192B (en) Use of strobilurins for treating malfunctions of the iron metabolism
ZA200902203B (en) Combination therapy
IL192851A0 (en) Compounds for the treatment of metabolic disorders
GB0818424D0 (en) An iron
ZA201101048B (en) Treating iron ore
IL195392A0 (en) Compounds for the treatment of metabolic disorders
GB0717649D0 (en) Process for the direct reduction of iron ore
PL2025804T3 (pl) Żelazko
IL192982A0 (en) Compounds for the treatment of metabolic disorders